GIGABYTE
15.2.2024 18:31:29 CET | Business Wire | Press release
GIGABYTE Technology, an IT pioneer whose focus is to advance global industries through cloud and AI computing systems, is coming to MWC 2024 with its next-generation servers empowering telcos, cloud service providers, enterprises, and SMBs to swiftly harness the value of 5G and AI. Featured is a cutting-edge AI server boasting AMD Instinct™ MI300X 8-GPU, and a comprehensive AI/HPC server series supporting the latest chip technology from AMD, Intel, and NVIDIA. The showcase will also feature integrated green computing solutions excelling in heat dissipation and energy reduction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215917651/en/
Inviting the AI-powered 5G Era, GIGABYTE will Present Next-Gen Servers for AI HPC, Telecom, and Green Computing Solutions at MWC 2024
Continuing the booth theme “Future of COMPUTING”, GIGABYTE's presentation will cover servers for AI/HPC, RAN and Core networks, modular edge platforms, all-in-one green computing solutions, and AI-powered self-driving technology. The exhibits will demonstrate how industries extend AI applications from cloud to edge and terminal devices through 5G connectivity, expanding future opportunities with faster time to market and sustainable operations. The showcase spans from February 26th to 29th at Booth #5F60, Hall 5, Fira Gran Via, Barcelona.
Tomorrow’s AI Supercomputers
The demand for AI-ready infrastructure and high-speed storage is escalating within the 5G framework, business operations, and academic research, driven by the exponential growth in data volume and the complexity of AI models. GIGABYTE will showcase its latest series of AI/HPC servers and an all-flash array (AFA) storage server. These servers support AMD Instinct™ MI300X OAM GPU modules, MI300A APUs, 5th Gen Intel® Xeon® Scalable Processors, NVIDIA HGX H100 8-GPU, and NVIDIA Grace Hopper Superchip, also leveraging the next-gen HBM3, ensuring hyper-speed data transmission. This technological leap is poised to advance exascale AI workloads and real-time big data analysis.
Flexible Server Architectures for the AI-enabled 5G Networks
The massive deployment of 5G applications requires flexibly configured digital infrastructure capable of supporting diverse IT ecosystems. GIGABYTE will introduce one of its modular edge platforms designed to manage a wide range of workloads, including networking, AI inferencing, and cloud computing. This platform offers seamless upgrades to accommodate multi-generational chip technologies and components, ensuring agile adaptation to rapid market changes with minimized maintenance costs.
In response to the rising demand for 5G and AI applications across businesses of varying scales, GIGABYTE will introduce its latest servers tailored for RAN and Core networks. These servers offer robust performance, catering to a range of computing needs from large-scale cloud-native workloads and telecom services to SMB IT operations. They excel in energy efficiency and provide expansion opportunities for AI-accelerated computing.
Sustainable AI and Cloud Computing Ensures Optimized TCO
At MWC, GIGABYTE is set to showcase its comprehensive all-in-one green computing solution, featuring a large-scale immersion cooling tank and two immersion-ready servers tailored for AI and cloud computing. The exhibit emphasizes their remarkable heat-dissipation capabilities and significantly lower power consumption. These features translate into a favorable total cost of ownership (TCO), highlighting GIGABYTE's commitment to sustainable and efficient computing solutions.
Future-Proof E-mobility Driven by Edge AI
Leveraging the 5G network and advanced AI algorithms, GIGABYTE's autonomous vehicle technology offers an exceptionally intelligent driving experience driven by edge AI. The high-speed data transmission performance ensures that GIGABYTE's Advanced Driver Assistance Systems (ADAS) and telematics efficiently process vast amounts of data from cameras, radars, and ultrasonic sensors. This enables the system to deliver precise real-time driving decisions, even in complex road conditions.
At GIGABYTE’s booth, enterprises can explore innovative and flexible computing solutions aligning with their strategies to gain a competitive edge in the AI-accelerated 5G future.
Visit GIGABYTE’s MWC event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215917651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom